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Abstract
Toll-like receptors (TLRs) recognize evolutionarily-conserved molecular patterns originating from invading microbes. In this
study, we were interested in determining if microbial ligands, which use distinct TLR2-containing receptor complexes,
represent unique signals to the cell and can thereby stimulate unique cellular responses. Using the TLR2 ligands, R-FSL1, S-
FSL1, Pam2CSK4, Pam3CSK4, and lipoteichoic acid (LTA), we demonstrate that these ligands activate NF-kB and MAP Kinase
pathways with ligand-specific differential kinetics in murine macrophages. Most strikingly, LTA stimulation of these
pathways was substantially delayed when compared with the other TLR2 ligands. These kinetics differences were associated
with a delay in the LTA-induced expression of a subset of genes as compared with another TLR2 ligand, R-FSL1. However,
this did not translate to overall differences in gene expression patterns four hours following stimulation with different TLR2
ligands. We extended this study to evaluate the in vivo responses to distinct TLR2 ligands using a murine model of acute
inflammation, which employs intravital microscopy to monitor leukocyte recruitment into the cremaster muscle. We found
that, although R-FSL1, S-FSL1, Pam2CSK4, and Pam3CSK4 were all able to stimulate robust leukocyte recruitment in vivo,
LTA remained functionally inert in this in vivo model. Therefore distinct TLR2 ligands elicit unique cellular responses, as
evidenced by differences in the kinetic profiles of signaling and gene expression responses in vitro, as well as the
physiologically relevant differences in the in vivo responses to these ligands.
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Introduction
Toll-like receptors (TLRs) are key components of the immune
system’s capacity to recognize infectious non-self and to mount a
rapid and effective immune response [1]. They are type I
transmembrane receptors, composed of an extracellular, leucine
rich repeat (LRR), ligand-recognition motif, as well as a highly
conserved, cytoplasmic, Toll/IL-1R (TIR), signaling-initiating
domain [2,3]. These receptors have evolved to recognize microbial
molecules of bacterial, viral, and fungal origin that are comprised
of molecular structures as diverse as proteins, lipopeptides,
glycolipids, as well as nucleic acids. These ligands bind to either
homo- or hetero-dimers of the TLR’s, often in combination with
different co-receptors [4].
TLR2, forming a heterodimer with either TLR1 or TLR6, is
responsible for the recognition of bacterial lipoproteins and
lipopeptides [5]. These ligands are derived from the bacterial cell
membrane, where they are anchored via lipid chains attached to a
polypeptide at a conserved N-terminal cysteine residue [6]. The
number of fatty acids coupled to the N-terminus of the polypeptide
is the crucial determinant in the ligand preference for specific
TLR2 heterodimers. Triacylated lipoproteins are produced by
most bacteria, with the exception of mycoplasma, and are
recognized by TLR2/1 heterodimer complexes [7]. The third
acyl chain in triacylated lipoproteins is attached via an amide bond
to the N-terminal cysteine. This reaction depends on the presence
of an N-acetyltransferase that is absent in mycoplasma and
therefore these organisms produce only diacylated lipopeptides,
which are recognized by TLR2/6 heterodimer complexes [8,9]. In
addition to these lipoproteins, TLR2 also recognizes and responds
to the Gram-positive bacterial cell wall component, lipoteichoic
acid (LTA) [10]. LTA is a diacylated, glycerophosphate polymer
and as such, this ligand is recognized by a TLR2/6 heterodimer
complex, presumably in a similar manner as the diacylated
lipoproteins [11]. In short, the TLR2 heterodimer complexes
allow for the accommodation of a structurally diverse ligand
repertoire. We were particularly interested in whether the use of
these distinct heterodimer complexes would translate to distinct,
receptor complex-specific, responses to TLR2 ligands.
TLR1, TLR2, and TLR6 are all members of the TLR1-family
of TLRs. These receptors share 66% sequence identity and are
located in tandem on the same chromosome in mammals [12].
The sequence similarity between TLR1 and TLR6 is in part the
result of gene conversion in a region encompassing the last four
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three quarters of the TIR domain [13]. These boundaries of gene
conversion are tightly conserved across species, presumably as a
result of an evolutionary pressure imparted by TLR1 and TLR6
shared functions, such as dimerization with TLR2 and the
initiation of signaling responses. Despite the strict similarities
between TLR1 and TLR6 there are some areas of divergence
within both the LRR-motifs and the TIR domains. We
hypothesized that the areas of free divergence within the TIR
domain and at the C-terminus of the proteins may have evolved
unique structure-function relationships, which could thereby
impart ligand-specific cellular responses to TLR2-containing
receptor complexes. Interestingly, employing distinct heterodimers
is not the only way that TLR2 is able to extend its ligand
repertoire, a forward genetics screen carried out by Beutler and
colleagues, has revealed the requirement for the co-receptor,
CD36, in order to mount a productive response to both LTA and
the R-enantiomer of diacylated lipopeptides [14].
Based on the divergent sequences within the TLR2 binding
partners TLR1 and TLR6, and the use of distinct, ligand-specific
co-receptors, we questioned whether these differences would
impart ligand-specific cellular responses to distinct TLR2 ligands.
We evaluated the response of both immortalized and primary
macrophages to different ligands that have been shown to signal
through TLR2/1, TLR2/6, or TLR2/6/CD36. The TLR ligands
used in this study were: the triacylated peptide, Pam3CSK3
(TLR2/1), the diacylated peptides, Pam2CSK4 (TLR2/6), S-
FSL1 (TLR2/6), R-FSL1 (TLR2/6/CD36), and the diacylated
glycerophosphate polymer, LTA (TLR2/6/CD36). We found that
the different TLR2 ligands stimulated downstream signaling
pathways with ligand-specific kinetic profiles in murine macro-
phages. Most strikingly, LTA consistently activated these pathways
with a substantially delayed kinetic profile as compared with the
other ligands. In addition, there was a delay in the rate of
production of a subset of TLR-responsive transcripts in response
to LTA (TLR2/6/CD36), as compared with R-FSL1 (TLR2/6/
CD36). However, 4 hours following the initial ligand administra-
tion, the transcriptional profiles activated by each ligand were
equivalent. Upon evaluating the in vivo pro-inflammatory
potential of these ligands, we found that although Pam3CSK3
(TLR2/1), Pam2CSK4 (TLR2/6), S-FSL1 (TLR2/6), and R-
FSL1 (TLR2/6/CD36), each induced robust leukocyte recruit-
ment into the cremaster muscle, LTA (TLR2/6/CD36), was
unable to cause any significant leukocyte recruitment. Therefore
we have shown that there are differences in the interpretation of
signals derived from ligands that signal through distinct TLR2-
containing receptor complexes, as evaluated using both in vitro
and in vivo assays.
Materials and Methods
Antibodies and Reagent
Pam3CSK4 and Pam2CSK4 were purchased from InvivoGen
(San Diego, CA). R- and S-FSL1 were purchased from EMC
microcollections (Tubingen, Germany). Ultrapure LTA was
provided by Dr. T. Hartung (University of Konstanz, Konstanz,
Germany). In this study we chose to use only synthesized di- or
triacylated ligands as well as highly purified LTA, in order to avoid
any of the prevailing issues of contamination. Antibodies for
phospho-SAPK/JNK, total-SAPK/JNK, phospho-erk1/2, total-
erk1/2, phospo-p38, phospho-c-jun, total-c-jun, phospho-ATF2,
and IkBa were purchased from Cell Signaling Technologies
(Beverly, MA). Anti-total p38 antibody was purchased from Santa
Cruz Biotechnology (Santa Cruz, CA).
Cell Culture and Western blotting
Western blots were performed as previously described [15].
Briefly, Raw 264.7 cells were plated in six-well tissue culture plates
and allowed to grow to 85% confluence. The cells were treated
with ligand for the indicated times, then lysed in Laemmili sample
buffer and sonicated. The samples were then resolved using 10%
SDS-PAGE. After electrophoresis, proteins were transferred to
nitrocellulose membranes, which were then blocked by incubation
in 5% BSA in TBS plus 0.05% Tween 20 (TBST). The
membranes were then incubated at 4uC overnight in the primary
antibody, washed for 40 minute in TBST, incubated for 1 h in
secondary antibody, and washed for another 40 minute in TBST.
The membranes were developed using an ECL substrate. For
experiments using primary bone marrow derived macrophages,
bone marrow was isolated from the femoral, tibial, and pelvic
bones of wildtype C57BL/6 or TLR2-/- mice. These cells were
cultured in DMEM + 10% FBS + penicillin/streptomycin/
glutamine + 10% L929 cell conditioned media for 7 days, feeding
the cells with fresh media on day 5. Treatments and Western blots
were then performed as described above. Image J software (NIH)
was used to quantify the Western blot signals.
RT-PCR
RNA was isolate from relevant cells using TrizolH (Invitrogen)
according to the manufacturer’s protocol. Total RNA was treated
with DNAase I and further purified by phenol extraction and
precipitated with sodium acetate and ethanol. cDNA was prepared
using superscript II (Invitrogen). For semi-quantitative RT-PCR the
cDNA was amplified using the following gene-specific primers for
TNFa,5 9TTGACCTCAGCGGCTGAGTTG39 and 59CCTGT-
AGCCCACGTCGTAGC39. The PCR products were prepared
with 106 DNA loading dye and run on a 2% TAE-agarose gel.
Pictureswere takenusing the Gel Doc 2000 system (BioRad), with the
saturated pixels function engaged so as to avoid overexposing the
image. Image J software (NIH) was used to quantifiy the bands on the
gel. In the case of the SABiosciences arrays, cDNA was diluted with
water according to the manufacture’s instructions and further mixed
with the PCR mastermix supplied by the manufacture. 100 mLo ft h i s
final mixture was added to each well of the array, (RT
2Profiler PCR
Array, Mouse Inflammatory Cytokines and Receptors), and run in
the ABI7000 RT-PCR machine using the following protocol, 95uC
10 minutes, 40 cycles of 15 seconds 95uC, and 1 minute 60uC. The
normalized threshold cycle (Ct) value for each gene, (DCt), was
determined by subtracting the Ct value of the housekeeping gene,
actin, from the Ct value of the gene of interest. The change in the Ct
value between control and treated samples for each gene of interest,
(DDCt), was then calculated and the fold change was determined
using the following formula, 2
‘(2DDCt).
Mice
Experiments were performed using male C57/B6 wildtype mice
purchased from The Jackson Laboratory (Bar Harbor, ME) or
TLR2-/- provided by Prof. Shizuo Akira (Osaka University,
Japan). These mice were maintained in a pathogen-free facility at
the University of Calgary’s Animal Resource Center. At the time
of use, mice weighed between 20 and 30 g and were 6–10 wk old.
Experimental animal protocols performed in this study were
approved by the University of Calgary Animal Care Committee
and met the guidelines of the Canadian Council for Animal Care.
In vivo evaluation of TLR2 ligands
Wildtype C57/B6 mice were given an intrascrotal injection of
150 mL of saline alone, or saline containing, TNFa (20 ng/g), LPS
Differential TLR2 Responses
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Pam2CSK4 (5 ng/g), R-FSL1 (5 ng/g), or S-FSL1 (5 ng/g).
Leukocyte adhesion and emigration were measured in the
cremasteric venules using intravital microscopy, 4.5 h following
the injection. Intravital microscopy was performed on male mice,
which were anaesthetized with an intraperitoneal injection of a
mixture of 10 mg/kg xylazine (Bayer, Animal Health, Toronto,
ON, Canada) and 200 mg/kg ketamine hydrochloride (Rogar/
STB, Montreal, QC, Canada). For all protocols, the left jugular
vein was cannulated to administer additional anaesthetic or drugs
when necessary. The mouse cremaster muscle preparation was
used to study the behaviour of leukocytes in the microcirculation
and adjacent muscle tissue as previously described [16]. Briefly, an
incision was made in the scrotal skin to expose the left cremaster
muscle, which was then carefully dissected free of the associated
fascia. The cremaster muscle was cut longitudinally with a cautery.
The testicle and the epididymis were separated from the
underlying muscle and were moved into the abdominal cavity.
The muscle was then held flat on an optically clear viewing
pedestal and was secured along the edges with 4-0 suture. The
exposed tissue was superfused with 37uC-warmed bicarbonate-
buffered saline (pH 7.4). An upright microscope (Mikron; Carl
Zeiss Canada, Don Mills, ON, Canada) with a 206objective lens
(Zeiss LD Plan-NEOFLUAR) and a 106 eyepiece was used to
examine the cremasteric microcirculation. A video camera (XR/
MEGA10-AM Panasonic, Osaka, Japan) was used to project the
images onto a monitor, and the images were recorded for playback
analysis using a DVD recorder. Three to five single unbranched
cremasteric venules (25 to 40 mm in diameter) were selected and
the average number of adherent and emigrated leukocytes was
determined offline during playback analysis. A leukocyte was
considered to be adherent if it remained stationary for at least 30
seconds, and total leukocyte adhesion was quantified as the
number of adherent cells within a 100-mm length of venule.
Leukocyte emigration was defined as the number of cells in the
extravascular space within the field of view, a 550 mm
2 area,
adjacent to the observed venule. Only cells adjacent to, and clearly
outside, the vessel under study were counted as emigrated.
Cremaster Histology
Wildtype male C57/B6 mice were given an intrascrotal
injection of saline, (150 ml), or saline containing various
proinflammatory ligands, as described in the results. Four hours
following ligand administration the cremaster muscle was
exteriorized, cut off, and fixed in 10% formalin. The cremaster
tissue was embedded in paraffin and 5 mm sections were cut and
stained with haematoxylin and eosin. The numbers of lympho-
cytes, monocytes, and neutrophils in the post capillary venules
were counted and differential percentages were scored.
Statistical analysis
The results are expressed as means 6 SEM. A one-way analysis
of variance was applied for multiple comparisons.
Results
Individual TLR2 ligands activate signaling pathways with
unique kinetic signatures in murine macrophages, in a
TLR2-dependent manner
To examine whether different TLR2 ligands activate cells in
ligand-specific ways, we first stimulated the murine macrophage/
monocyte cell line, Raw 264.7, for 0, 5, 15, 30, 45, or 60 minutes
with each of the TLR2 ligands: LTA (TLR2/6/CD36), R-FSL1
(TLR2/6/CD36), S-FSL1 (TLR2/6), Pam2CSK4 (TLR2/6), or
Pam3CSK4 (TLR2/1). Whole-cell lysates from these cells were
analysed by Western blotting and it was observed that the MAP
Kinase as well as the NF-kB signaling pathways, which are well
known targets of TLR activation, were differentially activated by the
different TLR2 ligands (Fig. 1). The activation of the MAP Kinase
pathways was determined by blotting for phospho-SAPK/JNK
(Fig. 1A) and phospho-p38 (Fig. 1B), and the degradation of IkBa
was indicative of the activation of the NF-kB pathway (Fig. 1C). The
ERK1/2 MAP Kinase pathway also showed similar activation
kinetics to the SAPK/JNK and p38 pathways (data not shown). All
of these pathways were rapidly and robustly activated when cells
were treated with R-FSL1, S-FSL1, Pam2CSK4 and Pam3CSK4,
although there were reproducible differences in the activation
kinetics between these ligands. R-FSL1 consistently activated all
signaling pathways very quickly; by 5 minutes the phospho-MAP
Kinase pathway activation markers and the degradation of IkBa
were apparent and these signals generally subsided by 30–45
minutes. Pam2CSK4 followed this trend closely but tended to be
slightly delayed as compared with R-FSL1. In contrast, Pam3CSK4
and S-FSL1 did not lead to any visible activation of the MAP Kinase
or NF-kB pathways until the 15 minute timepoint and this signal
generally remained until the 45–60 minute timepoint. Although
these ligands were similar, Pam3CSK4 was slightly delayed when
compared with S-FSL1. However, the biggest difference in the
kinetics of activation between the different TLR2 ligands was
observed when LTA was compared with the other TLR2 ligands.
LTA treatment did not activate the MAP Kinase or NF-kB
pathways until the 30 minute timepoint, and these signals began to
subside by the 60 minute timepoint. Figure 1D shows the relative
quantification ofthe kinetics of activation of these pathwaysforthree
independent experiments. The observed differences in the kinetic
profiles between the distinct TLR2 ligands were not the result of
differences in the effective concentrations of the ligands used. When
ligand concentrations were increased by five-fold, the relative kinetic
profiles were exactly the same as that observed using our initial
concentration, as shown for p38 MAP Kinase (Fig. 1E) and SAPK/
JNK (data not shown). Although the overall kinetic profiles were the
same, the signal strength of activation of these pathways was more
robust when the higher ligand concentration was used. Therefore in
the remaining studies we chose to continue using the initial ligand
concentrations, as this resulted in consistent cellular stimulation,
which was not altered upon increasing the ligand concentration, and
are consistent with what has been used in the literature.
To ensure that the difference in activation kinetics we observed
in the Raw 264.7 cells was not a cell-line specific phenomenon,
similar experiments were performed using bone marrow derived
macrophages, isolated and derived from the bone marrow of
wildtype C57/B6 mice. When these macrophages were fully
differentiated and treated with the TLR2 ligands: LTA, R-FSL1,
S-FSL1, Pam2CSK4, or Pam3CSK4, once again there were
ligand-specific activation kinetics of the p38, SAPK/JNK, and NF-
kB pathways, which precisely matched those observed using the
immortalized Raw 264.7 cells (Fig. 2A–C). These primary bone
marrow derived macrophages were also used to ensure that the
responses to these ligands were TLR2-specific. Bone marrow from
TLR2-/- mice was used to differentiate into macrophages and
these cells were treated with the different TLR2 ligands alongside
the macrophages derived from wildtype bone marrow. When these
TLR2-/- macrophages were evaluated with respect to the
activation of MAP Kinase or NF-kB pathways, these ligands were
unable to activate any pathways in these cells, indicating the
TLR2-dependence of all these responses. As expected the TLR4
ligand, LPS was able to active wildtype and TLR2-/- cells
(Fig. 2A–C). To further verify that these ligands only stimulate
Differential TLR2 Responses
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marrow derived macrophages isolated from both strains of mice,
with the TLR2 ligands: LTA, R-FSL1, S-FSL1, Pam2CSK4, or
Pam3CSK4 for 4 hours. These cells were then lysed and RNA was
extracted for RT-PCR-based evaluation of pro-inflammatory
responses. The mRNA transcript for TNFa was substantially
upregulated in wildtype cells treated with each of the TLR2
ligands, or when LPS was included as a positive control. However,
the TLR2-/- cells did not contain an increased amount of the
TNFa transcript when cells were treated with the TLR2 ligands.
LPS was still able to stimulate TNFa transcript production in these
TLR2-/- cells (Fig. 2D).
The difference in the activation kinetics of the MAPK
Kinase pathways translates to a difference in the
activation kinetics of downstream transcription factors
Since we observed differences in the activation kinetics of the
MAP Kinases, we wanted to evaluate whether this translated to
differences in the activation of their downstream transcription
factors. We evaluated the activation of the transcription factor, c-
jun, by its phosphorylation on an activating residue, Ser63, as well
as the electrophoretic shift caused by the phospho-modification of
the protein when Western blots were probed with a total anti-c-jun
antibody (Fig. 3A and B). Consistent with our earlier observations,
there were reproducible, albeit subtle, kinetic differences in the
phosphorylation and presumed activation of c-jun when Raw
264.7 cells were treated with, R-FSL1, S-FSL1, Pam2CSK4, or
Pam3CSK4. More dramatically, the activation of c-jun by LTA
was much weaker than that observed with any of the other TLR2
ligands and once again this activation was not apparent until 30–
45 minutes, which was substantially delayed when compared with
the other TLR2 ligands. In wildtype bone marrow derived
macrophages, the kinetics of c-jun activation also followed similar
kinetic profiles, as judged by the electorphoretic shift of total c-jun
(Fig. 3C). Another transcription factor that is downstream of the
initiating MAP Kinases, ATF2, also showed differential activation
kinetics in wildtype bone marrow derived macrophages, as
measured by Thr71 phosphorylation of this protein (Fig. 3D).
Figure 1. Kinetic profiles of signaling pathway activation in Raw 264.7 cells, in response to TLR2 ligands. Raw 264.7 cells treated with
LPS (100 ng/mL), LTA (1 mg/mL), R-FSL-1 (100 ng/mL), S-FSL-1 (100 ng/mL), Pam2CSK4 (100 ng/mL), Pam3CSK4 (100 ng/mL) for 0, 5, 15, 30,45, or 60
minutes were used to perform Western Blot analysis of A) phospho-SAPK/JNK activation signal and total-SAPK/JNK protein amounts, and B) Phospho-
p38 activation signal and total-p38 protein amounts and C) total IkBa protein amounts. In D) the normalized levels of total IkBa protein, phospho-
SAPK/JNK activation signal, or phospho-p38 activation signal are shown for n=3 experiments. Western blot band intensities were quantified using
Image J software (NIH) and all signals were background subtracted and then normalized to peak activation levels. Therefore peak activation was
given a value of 1. In E) Raw 264.7 cells, stimulated with 5-fold the initial ligand concentrations, LPS (500 ng/mL), LTA (5 mg/mL), R-FSL-1 (500 ng/mL),
S-FSL-1 (500 ng/mL), Pam2CSK4 (500 ng/mL), Pam3CSK4 (500 ng/mL) for 0, 5, 15, 30,45, or 60 minutes were used to perform Western blot analysis of
phospho-p38 activation signal and total-p38 protein amounts. Results are representative of n=3 independent experiments.
doi:10.1371/journal.pone.0005601.g001
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and NF-kB pathways downstream of different TLR2
ligands does not translate to different gene expression
profiles
Considering that ATF2 and c-jun, both components of the AP-1
transcription factor complex, and the primary innate immune
regulator, IkBa, are each activated with differential kinetics by the
TLR2 ligands we tested, we wanted to evaluate the possible
influence that these differential signaling kinetics would have on
the transcriptional response of macrophages to the different TLR2
ligands. We employed the real-time RT
2-Profiler
TM PCR Array
System from SABiosciences, to evaluate the transcriptional
response of known TLR response genes. Raw 264.7 cells were
treated for four hours with either: LTA, R-FSL1, S-FSL1, or
Pam3CSK4, and subsequently analysed for the upregulation of
pro-inflammatory transcripts. Judged by these real-time RT-PCR
arrays, all of the genes that were upregulated following treatment
with each of the TLR2 ligands were the same (Fig. 4). However,
there were some differences in the degree to which different genes
transcripts were upregulated. Of the 11 genes that were shown to
be consistently upregulated by the TLR2 ligands, three genes;
ccl3/MIP1a, IL1a, and the TNF receptor superfamily member
1b, were all upregulated to a lesser degree 4 hours following
stimulation with R-FSL1 as compared with the other TLR2
ligands.
The transcriptional response of some genes is delayed in
response to LTA versus R-FSL1
To further evaluate whether different TLR2 ligands are able to
influence the transcriptional response of murine macrophages in
distinct ways, we examined the kinetics of the transcriptional
response to these ligands in Raw 264.7 cells. Since these ligands can
cause distinct kinetics of activation of downstream signaling
pathways, we chose to evaluate the ligands that showed the greatest
differences in these assays, LTA and R-FSL1. Raw 264.7 cells were
treatedfor 0, 5, 15, 30,45, 60, 90,and 120 minutes with either LTA
or R-FSL1, and RNA was extracted from these cells and evaluated
for the presence of the TNFa transcript. In cells treated with R-
FSL1, there was a rapid up-regulation of TNFa mRNA transcripts,
as demonstrated by RT-PCR, with cDNA synthesis apparent from
these samples as early as 15 minutes following stimulation. However
in cells that had been treated with LTA, evidence of the TNFa
transcripts was not detectable until 30 minutes (Fig. 5A–B). This is
consistent with the kinetics of activation of the signaling pathways
being delayed upon treatment of cells with LTA as compared with
the other TLR2 ligands tested. To extend these results to other
inflammatory genes we once again employed the real-time RT
2-
Profiler
TM PCR Arrays. RNA extracted from Raw 264.7 cells,
which had been treated with LTA or R-FSL1 for 15 or 30 minutes,
was used to perform the arrays (Fig. 5C). We found both R-FSL1
and LTA ultimately led to the up-regulation of the same genes;
Figure 2. Kinetic profiles of signaling pathway activation in response to TLR2 ligands in BMDMs. Primary bone marrow derived
macrophages (BMDMs), isolated from either wildtype or TLR2-/- mice, treated with LPS (100 ng/mL), LTA (1 mg/mL), R-FSL-1 (100 ng/mL, R), S-FSL-1
(100 ng/mL, S), Pam2CSK4 (100 ng/mL, P2), Pam3CSK4 (100 ng/mL, P3) for 0, 5, 15, 30,45, or 60 minutes were used to perform Western blot analysis of
A) phospho-SAPK/JNK activation signal and total-SAPK/JNK protein amounts, B) Phospho-p38 activation signal and total-p38 protein amounts, and C)
total IkBa protein amounts. In D) RT-PCR was performed on mRNA isolated from wildtype or TLR2-/- bone marrow derived macrophage treated with
each ligand for 4 hours and the TLR2-dependence of cell activation leading to TNFa mRNA transcription is shown. All results are representative of
n=3 independent experiments.
doi:10.1371/journal.pone.0005601.g002
Differential TLR2 Responses
PLoS ONE | www.plosone.org 5 May 2009 | Volume 4 | Issue 5 | e5601however, the transcriptional response of some genes in response to
LTA was delayed. TNFa, cxcl1/KC, ccl7/MCP3, IL10, and ccl4/
MIP1b each exhibited this delayed transcriptional response to LTA
as compared with R-FSL1. In contrast, the other gene transcripts
that we found to be up-regulated at either the 15 or 30 minute
timepoint were equally responsive to both R-FSL1 and LTA. IL1b,
IL10 receptor b, gp130, aM Integrin, and b2 Integrin gene
transcription was all up-regulated to an equivalent extent and with
similar kinetic profiles upon treatment with either R-FSL1 or LTA.
R-FSL1, S-FSL1, Pam2CSK4, and Pam3CSK4 each induce
robust leukocyte recruitment in vivo, in contrast, LTA is
unable to induce leukocyte recruitment in vivo
Following from our observations in vitro we were interested in
evaluating the response to distinct TLR2 ligands in an in vivo
setting. Our group has previously investigated the in vivo
responses to the TLR2 ligand, LTA, and we found that LTA is
unable to induce leukocyte recruitment when administered in vivo
[17]. These studies showed that following an intrascrotal injection
of highly purified LTA, there is no significant increase in the
number of leukocytes rolling along the venules, adhering to the
venules, or emigrating into the tissue of the murine cremaster
muscle. In our current study we evaluated the inflammatory
potential of other known TLR2 ligands to determine if the absence
of leukocyte recruitment observed upon in vivo stimulation with
LTA was a characteristic of all TLR2 ligands, or phenomenon
that is unique to LTA. Under control conditions, 4 hours following
an intrascrotal injection of saline, there were very few cells
adhering to the post-capillary venules (Fig. 6A) or that had
emigrated into the tissue (Fig. 6B) of the murine cremaster muscle.
Upon intrascrotal injection of the positive controls, LPS or TNFa,
there were approximately 12–15 leukocytes adherent (Fig. 6A)
within the post-capillary venules and 30 leukocytes that had
emigrated (Fig. 6B) into the tissue, 4 hours post-stimulation. In
contrast, the intrascrotal administration of the TLR2 ligands
yielded mixed results. Whereas LTA did not induce any significant
leukocyte adhesion (Fig. 6A) or emigration (Fig. 6B), the other
TLR2 ligands that were tested: R-FSL1, S-FSL1, Pam2CSK4,
and Pam3CSK4, each induced on average between 15–19 cells to
adhere (Fig. 6A) within the venules and 30–70 cells to emigrate
(Fig. 6B) into the tissue. To ensure that the lack of a response to
LTA was not simply due to the fact that LTA may require a higher
active concentration, 56 the initial concentration of LTA was
administered by intrascrotal injection and once again no
significant adhesion (Fig. 6A) nor emigration (Fig. 6B) was
observed within the cremaster muscle. These results are in
agreement with our previous studies with LTA [17]. LTA is
unique among the TLR2 ligands tested in the cremaster model, in
that this ligand appears to be functionally inert with respect to
leukocyte recruitment, whereas the other TLR2 ligands were able
to induce robust leukocyte recruitment. Since LTA was not
leading to the recruitment of cells into the tissue we also recorded
the circulating leukocyte counts in order to ensure that LTA was
not causing leukopenia. Figure 6C shows that none of the ligand
treatments caused a reduction in the circulating leukocyte
numbers. Finally, cremaster tissue sections were stained with
haematoxylin and eosin in order to histologically examine the
types of leukocytes that were recruited into the vasculature of the
murine cremaster muscle. The relative percentages of lympho-
cytes, monocytes, and neutrophils, as a percentage of total
leukocytes within post-capillary venules, are shown in Figure 6D.
The vast majority (.85%) of leukocytes within these venules were
neutrophils, and there were no significant differences between the
profiles of cells recruited into the post-capillary venules in response
to the different TLR2 ligands (Pam2CSK4, Pam3CSK4, S-FSL1,
or R-FSL1). Lipoteichoic acid did not cause any cell recruitment
into the cremaster muscle and therefore the relative percentages of
cells within the venules are not shown.
Discussion
Our studies have revealed that although the TLR2 ligands, R-
FSL1, S-FSL1, Pam3CSK4, Pam2CSK4, and LTA each activate
typical TLR-dependent pathways in vitro, the kinetics of this
activation is substantially delayed in response to LTA as compared
with the other TLR2 ligands. LTA is also unable to stimulate
leukocyte recruitment in vivo; whereas, the other TLR2 ligands
are all able to provoke robust leukocyte recruitment into the
murine cremaster muscle, following intrascrotal injection of the
ligands. Together these distinct responses represent substantial,
Figure 3. Kinetic profiles of transcription factor activation in
response to TLR2 ligands. Raw 264.7 cells were treated with LPS
(100 ng/mL), LTA (1 mg/mL), R-FSL-1 (100 ng/mL), S-FSL-1 (100 ng/mL),
Pam2CSK4 (100 ng/mL), Pam3CSK4 (100 ng/mL) for 0, 5, 15, 30,45, or 60
minutes and lysates were used for Western blot analysis of A) total c-jun
and B) phospho-Ser63 c-jun. Wildtype bone marrow derived macro-
phage were treated in a similar way as the Raw 264.7 cells in A and B
and lysates were used for Western blot analysis of C) total c-jun and D)
phospho-Thr71 ATF2. All results are representative of n=3 independent
experiments.
doi:10.1371/journal.pone.0005601.g003
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PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5601Figure 4. Transcriptional profile in response to distinct TLR2 ligands. Raw 264.7 cells were treated for 4 hours with LTA (1 mg/mL), R-FSL-1
(100 ng/mL, R), S-FSL-1 (100 ng/mL, S), or Pam3CSK4 (100 ng/mL, P3), mRNA was extracted and used to perform arrays using the RT
2Profiler PCR
Array, Mouse Inflammatory Cytokines and Receptors (SABiosciences). Genes that were consistently upregulated greater than 2 fold over n=3
independent experiments are shown. (* p,0.05).
doi:10.1371/journal.pone.0005601.g004
Figure 5. Kinetic profiles of transcriptional responses to different TLR2 ligands. Raw 264.7 cells were treated for 0, 5, 15, 30, 45, or 60
minutes with either R-FSL1 (100 ng/mL, R) or LTA (1 mg/mL, L). The transcriptional upregulation of the TNFa gene was monitored using A) RT-PCR and
the results of n=3 independent experiments of semi-quantitative PCR were analyzed using Image J software (NIH) and are presented in B). In C), the
kinetic profile of the transcriptional response to other TLR2-responsive genes was analyzed using the RT
2Profiler PCR Array, Mouse Inflammatory
Cytokines and Receptors (SABiosciences). Genes that were consistently upregulated greater than 2 fold over n=3 independent experiments at these
timepoints are shown. (* p,0.05, ** p,0.01, and *** p,0.001).
doi:10.1371/journal.pone.0005601.g005
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signal initiated by different TLR2 ligands.
Similar to what has already been extensively characterized in
the literature; we show that each of the TLR2 ligands is able to
activate the downstream MAP Kinase and NF-kB pathways in
vitro in murine macrophages. However, when the kinetic profiles
of activation of these pathways were considered, we found
substantial differences between the kinetics of activation induced
by each TLR2 ligand. This was most apparent when the activation
kinetics induced by LTA was compared with the other TLR2
ligands tested. LTA was dramatically delayed in activation of both
the MAP Kinase pathways as well as the NF-kB pathways.
Although these kinetic differences did translate to the level of
downstream transcription factors, they did not affect the overall
gene expression patterns activated downstream of the different
TLR2 ligands 4 hours following cellular stimulation with each
ligand. This is consistent with a recent study which used extensive
microarray analysis and also showed that distinct TLR2 ligands
did not induce unique gene expression profiles [18]. However,
when we evaluated the kinetics of the transcriptional activation, we
found that although LTA and R-FSL1 activated the same
transcriptional response, treatment with LTA did not result in
the transcription of many inflammation-associated genes nearly as
quickly as did R-FSL1. This is in line with our observation that the
kinetics of activation of upstream signaling pathways is delayed
upon cellular stimulation with LTA as compared with the other
TLR2 ligands. Notably, not all of the upregulated transcripts were
delayed upon treatment with LTA versus R-FSL1. Some genes,
IL10 receptor b, gp130, aM Integrin, and b2 Integrin, showed
robust transcription at the 15 minute timepoint, which is well
before the observable activation of the upstream signaling
pathways by LTA. It is possible that the limited resolution of
Western blots cannot fully appreciate the interpretation of local
activation of pathways within the cell. Therefore there may be
Figure 6. Evaluation of the in vivo pro-inflammatory capacity of distinct TLR2 ligands. Wildtype, male, C57/B6 mice were given
intrascrotal injections of either saline alone, or saline containing TNFa (20 ng/g), LPS (10 ng/g), Pam3CSK4 (5 ng/g), Pam2CSK4 (5 ng/g), S-FSL1 (5 ng/
g, S), R-FSL1 (5 ng/g, R), LTA (5 or 25 ng/g). After 4 hours the cremaster muscle was exteriorized and the degree of leukocyte A) adhesion and B)
emigration was measured. In C) total circulating leukocytes were counted in the blood. In D) the relative percentages of lymphocytes (Ly), monocytes
(M), and neutrophils (N) within the post-capillary venules were determined from haematoxylin and eosin stained cremaster tissue sections. All results
are representative of n$3 independent experiments. (*** p,0.001).
doi:10.1371/journal.pone.0005601.g006
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well before they become observable using Western blot analysis.
Clearly, the cellular mechanisms that regulate gene expression are
multifaceted and this may explain our observation that genes
induced downstream of LTA fall into two distinct categories; those
that are delayed in their response as compared with R-FSL1 and
those that are induced with comparable kinetics to R-FSL1. For
example, it is possible that the regulation of chromatin dynamics,
and thereby the accessibility of the DNA to transcriptional
machinery, is impaired at specific loci in response to LTA as
compared with R-FSL1. This mechanism of transcriptional
specificity has been demonstrated to help establish the unique
transcriptional responses downstream of distinct TLRs or to allow
sequential gene expression profiles to be initiated downstream of
TLR4 [19,20]. In a similar way, the activation of some
transcriptional programs downstream of TLR4 require strong,
sustained activation of NFkB pathways in order to feed forward
and activate other transcription factors, such as C/EBPd, which
further enhance the transcription of a subset of genes [21].
Considering these dynamic regulatory mechanisms, it is reason-
able to speculate that the differences in the kinetics of activation of
downstream pathways, activated by the distinct TLR2-complex
containing ligands, would influence the overall cellular responses
to these ligands. The complementary in vivo observations we
present in this study may be the consequence of some of these
distinct regulatory responses working within the tissue to establish
a productive inflammatory response to R-FSL1, S-FSL1,
Pam3CSK4, and Pam2CSK4; whereas the response to LTA is
ultimately unproductive in vivo.
Contrary to our in vivo results, there are reports that LTA
causes acute pulmonary inflammation in vivo [22]. We have also
observed that intratracheal administration of LTA to mice resulted
in substantial neutrophil infiltration into the lung (data not shown).
The striking difference between our results in the cremaster and
these studies may be reflective of cell type specific, and thus organ
specific, immune responses.
We anticipate that the differences in the kinetic signaling
responses to the TLR2 ligands may be as a result of differences in
the heterodimer selection or the use of distinct co-receptors by
individual ligands. To date, there have not been any TLR1- or
TLR6-specific adaptor proteins identified, which would impart
TLR1- or TLR6-specific signaling responses. However the unique
in vitro and in vivo responses to distinct ligands that we report in
this study may support this as a legitimate avenue of investigation.
In terms of co-receptors, TLR2 has been shown to require CD36
to respond to diacylated ligands. CD36 has been shown to activate
Src-family Kinases [23], and this may impact the overall signaling
milieu and eventual response to these ligands. However, as both
R-FSL1 and LTA have been shown to employ this co-receptor this
could not explain the differential response to LTA versus R-FSL1
that we observed in this study. Recently, integrin b3 was shown to
be involved in the response to both lipopeptides and LTA [24].
This integrin forms part of the TLR2-containing ligand recogni-
tion complex and is essential for proinflammatory cytokine
production in response to these ligands. It is possible that other
distinct, heretofore unidentified co-receptors may be responsible
for the distinct responses to the different TLR2 ligands we
observed in this study.
In addition to the distinct heterodimer and co-receptor
involvement in ligand recognition, the cellular trafficking of these
complexes following ligand stimulation may influence the final
cellular response. The growth factor signaling field has shown that
for efficient signaling to occur, signals must be propagated from
distinct cellular locations. For example, an endocytosis-defective
dynamin mutant that blocks internalization of the EGF receptor
has been found to prevent maximal EGF-induced ERK activation
[25]. Similarly within the TLR field, Medzithov and colleagues
have recently shown that TLR4 driven, Myd88/Mal-dependent
and TRIF/TRAM-dependent signaling pathways are initiated
from the plasma membrane and endosomal compartments,
respectively [26]. In the case of TLR2, it has been shown that
inhibiting internalization of LTA can actually increase the in vitro
cellular response to ligand stimulation in murine macrophages.
Internalized LTA co-localizes with ER, Golgi, and endosomal
markers, in direct contrast to the other TLR2 ligands, Pam3CSK4
and FSL-1, which are found in endocytic vesicles. Additionally, or
as a direct result of these differences, LTA is internalized much
more quickly than these other TLR2 ligands [27]. Taken together,
this evidence may indicate that the molecular structure of LTA
dictates a vastly different internalization program than the other
TLR2 ligands, which may impede the ability of this ligand to
promote robust signaling and a productive immune response.
As discussed, when macrophages were treated with LTA, the
activation of the MAP Kinase and NF-kB pathways was delayed by
approximately 15 minutes when compared with the activation
profiles of the other TLR2 ligands. We suspected that this
difference in activation kinetics would translate to greater
differences in the cellular response to these ligands. As a precedent,
the differential response of PC12 cells to NGF, which causes
neuronal differentiation, versus EGF, which yields a weak
proliferative response, has been attributed to sustained versus
transient activation of the ERK MAP Kinase pathway [28]. Within
the TLR4 field, it is well known that early activation of downstream
signaling pathways is dependent on MyD88/Mal-dependent
signaling from the plasma membrane and that these pathways
demonstrate sustained activity on the basis of continued stimulation
through the TRIF/TRAM-dependent signaling complex at the
endosome. Recently, it has been shown that in the absence of
CD14, TLR4 retains signaling abilities but only through the
MyD88/Mal-dependent pathway [29]. Moreover, specific ligands
have been shown to utilize this paradigm in a functionally relevant
manner. Rough LPS, (poorly glycosylated), does not require CD14,
and smooth LPS, (highly glycosylated), does require CD14 to
activate cells in a TLR4 dependent manner [29]. The differences in
the pathways activated downstream of these ligands is of
paramount importance to the types of genes which are upregulated
in response to these stimuli. TLR4 has also been shown to activate
only the TRIF/TRAM-dependent pathway downstream of the
vesicular stomatitis virus glycoprotein G. This activation is
principally dependent on TRAM and allows for only a type I
interferon response in the absence of a MyD88/Mal-dependent
activation of NFkB [30]. The specific intricacies of each ligand
notwithstanding, the differential activation is manifest as a
differential kinetics of activation, as MyD88/Mal-dependent versus
TRIF/TRAM-dependent pathways tend to proceed quickly from
the plasma membrane and delayed from the endosome, respec-
tively. These findings represent a model whereby both the
supramolecular TLR4-containing complex, in cooperation with
the nature of the ligand, determine how the receptor will signal and
ultimately direct the cellular and organismal response. Although we
did not observe any lasting, distinct transcriptional responses to the
different TLR2 ligands, the distinct physiologic response to LTA
versus the other TLR2 ligands argues that the kinetic differences in
pathway activation may indeed have profound effects on the
cellular responses to these different ligands. Therefore, the results
presented herein may herald the identification of ligand-specific
intricacies, which are reminiscent of the TLR4 signaling paradigm,
within the biology of TLR2 signaling pathways.
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